PDCD1 and metastatic melanoma: For example, retrospective data indicate that metastatic melanoma patients who suffered from a serious anti-CTLA-4-related adverse event (defined as grade 3–4 and/or requiring systemic immunosuppression) were able to be safely started on an anti-PD-1 agent4,33.